HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EPI-002

an androgen receptor activation function-1 inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzhydryl Compounds
        EPI-002: 1
- Alcohols: 595
  - Sugar Alcohols: 143
    - Triose Sugar Alcohols: 4
      - Glycerol: 4398
        EPI-002: 1
Carbohydrates: 22023
- Sugar Alcohols: 143
  - Triose Sugar Alcohols: 4
    - Glycerol: 4398
      - EPI-002: 1

Experts

1.	Banuelos, Carmen A: 1 article (01/2016)
2.	Caley, Daniel P: 1 article (01/2016)
3.	Imamura, Yusuke: 1 article (01/2016)
4.	Kato, Minoru: 1 article (01/2016)
5.	Leung, Jacky K: 1 article (01/2016)
6.	Mawji, Nasrin R: 1 article (01/2016)
7.	Sadar, Marianne D: 1 article (01/2016)
8.	Wang, Jun: 1 article (01/2016)

Related Diseases

1.

Prostatic Neoplasms (Prostate Cancer)

01/01/2016 - "It is currently unknown how blocking the PI3K/Akt/mTOR pathway impacts prostate cancer driven by AR-Vs. Here, we evaluated the efficacy and mechanism of combination therapy to block mTOR activity together with EPI-002, an AR N-terminal domain (NTD) antagonist that blocks the transcriptional activities of FL-AR and AR-Vs in models of CRPC. "
01/01/2016 - "To determine the functional roles of FL-AR, AR-Vs, and PI3K/Akt/mTOR pathways, we employed EPI-002 or enzalutamide and BEZ235 (low dose) or everolimus in human prostate cancer cells that express FL-AR or FL-AR and AR-Vs (LNCaP95). "

Related Drugs and Biologics

1.	Everolimus
2.	enzalutamide
3.	dactolisib

Related Therapies and Procedures

1.	Therapeutics